Jump to any asset
850 assets, updated daily
As of September 12, 2026, Edwards Lifesciences Corporation (EW) trades at $84.37. CleaRank Financial AI rates it Sell with a fair value of $84.37, in line with the current price. Wall Street's consensus target is $101.50 across 29 analysts. RSI at 25 is in oversold territory, and the price is below its 50-day average of $89.23.
Edwards Lifesciences Corporation (EW)
Edwards Lifesciences Corporation NYSE
$84.37
-2.400 (-2.77%)
At close: Sep 11, 4:00 PM EDT
AI Analyst Consensus
21 / 100
Edwards Lifesciences Corporation (EW) is trading at $84.37, below its 50-day and 200-day moving averages ($89.23 and $84.97), indicating a bearish technical trend. The company's RSI is at 24.81, signaling oversold conditions. Wall Street analysts maintain a 'Buy' consensus with a median price target of $101.50, suggesting a 20.3% upside potential from the current price. However, insider activity shows a 'Net Seller' position with $34.6 million in sales versus no reported purchases, indicating moderate selling pressure from management. Revenue growth has been positive, with the current year estimated at $6.8 billion, an 11.00% increase year-over-year, and next year projected at $7.4 billion, an 10.00% increase. The company's P/E ratio stands at 51.60, which is significantly higher than the sector median of 31.9, suggesting a premium valuation. Despite the strong revenue growth estimates and positive analyst sentiment, the current technical setup and insider selling warrant caution.
EW Price Analysis
Market Metrics
Open
$87.51
Day Range
$83.81 to $87.76
Prev Close
$86.77
Volume
3.80M
52-Week Range
$72.30 to $96.29
Market Cap
$48.58B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Trading at a significant premium to sector peers (+62%), suggesting market expectations for superior growth or market position.
EW Analysis
Company's Health
3/5
AI Technical Analysis
Edwards Lifesciences Corporation's stock is currently trading below its 50-day SMA of $89.23 and its 200-day SMA of $84.97, indicating a bearish trend. The RSI is at an oversold level of 24.81, suggesting a potential for a short-term bounce. MACD is at -0.786864842418538, also indicating bearish momentum. The nearest support level is the current price at $84.37, with resistance found at the 200-day SMA of $84.97 and the 50-day SMA of $89.23. Volume has been above average recently, with the latest volume at 3.79 million compared to an average of 2.81 million, suggesting increased investor interest, though currently in a downtrend.
ProTips
- Monitor upcoming earnings reports closely for any signs of acceleration in revenue growth or improved profitability to justify the current valuation.
- Given the oversold RSI, consider waiting for confirmation of a technical bounce before initiating new positions.
- The moderate insider selling warrants attention; track future insider transactions for any shifts in sentiment.
Key Catalysts
Bullish
Strong Q3 2026 Earnings Beat
If Edwards Lifesciences reports Q3 2026 EPS significantly above the $0.78 actual from Q2 2026 and the analyst estimate of $0.74, it could signal renewed fundamental strength and drive the stock higher.
Source: Analyst EstimatesBullish
Positive Clinical Trial Results
Positive outcomes from ongoing clinical trials for new medical devices could significantly boost investor confidence and provide a strong catalyst for share price appreciation.
Source: Company PipelineBearish
Continued Insider Selling
Sustained or increased insider selling activity, particularly by company officers, could signal a lack of confidence in future performance and exert downward pressure on the stock price.
Source: Insider TransactionsBearish
Valuation Compression
If the market continues to de-rate high-multiple stocks, EW's P/E ratio of 51.60 could face significant compression, leading to a price decline even if revenue growth remains steady.
Source: Market TrendsMarket Outlook
The base case for Edwards Lifesciences Corporation over the next 6-12 months suggests continued pressure given the current technical setup and valuation concerns. While revenue growth is projected to remain strong at around 10-11% annually, the stock's P/E ratio of 51.60 remains a significant overhang compared to the sector median of 31.9. The oversold RSI at 24.81 may provide some short-term support, but a sustained move higher would require a clear catalyst to justify the premium valuation and overcome the moderate insider selling. Upside catalysts could include stronger-than-expected earnings beats that significantly surpass analyst estimates, positive developments in new product pipelines, or a broader market rotation into healthcare value stocks. Conversely, downside risks include continued insider selling, a failure to meet revenue growth expectations, increased competition in the medical device sector, or a general market downturn that disproportionately affects high-valuation stocks. A breach below the $84.37 current price could signal further declines towards the lower end of the analyst price targets.
Key Statistics
| Market Cap | 48.58B |
|---|---|
| P/E Ratio | 51.60 |
| EPS (TTM) | 1.67 |
| Dividend Yield | 0.00% |
| 52 Week High | 96.29 |
| 52 Week Low | 72.30 |
Edwards Lifesciences Corporation exhibits a high P/E ratio of 51.60, considerably above the healthcare sector median of 31.9, indicating a potentially overvalued stock based on current earnings. While the company demonstrates strong revenue growth, with current year estimates at 11.00% and next year at 10.00%, its earnings per share (EPS) of $1.67 does not fully justify the current valuation. The company's return on equity (ROE) is 6.9%, which is below the sector median of 6.9%, further questioning the efficiency of its operations relative to its peers. The lack of significant insider selling, coupled with moderate insider selling totaling $34.6 million, adds a layer of concern to the fundamental picture.
Earnings & Growth Analysis
Edwards Lifesciences Corporation most recently reported Q2 2026 earnings on July 23, 2026, with an EPS of $0.78, beating the estimate of $0.74 by 5.41%, though the stock price declined by 1.42%. Prior to this, Q1 2026 earnings on April 23, 2026, showed an EPS of $0.78, beating estimates by 6.85% and resulting in a 5.56% price increase. The company missed estimates in Q4 2025 and Q3 2025, indicating an inconsistent earnings performance over the past year.
Key Risks
Edwards Lifesciences Corporation faces significant risks including its elevated valuation, with a P/E ratio of 51.60 compared to the sector median of 31.9. The stock is currently trading below key technical indicators, including the 50-day and 200-day SMAs, and exhibits oversold RSI conditions, suggesting potential for further downside. Additionally, moderate insider selling totaling $34.6 million indicates a lack of strong conviction from management at current price levels.
Technical Indicators
| RSI (14) | 24.81 |
|---|---|
| MACD | -0.79 |
| SMA 50 | 89.23 |
| SMA 200 | 84.97 |
RSI
Oversold
SMA Cross
Bullish
Price vs SMA
Bearish
MACD
Bearish
Golden Cross in effect with the 50-day SMA ($89.23) above the 200-day SMA ($84.97), price is trading below the 50-day SMA, RSI at 24.8 suggests oversold conditions; potential bounce setup.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.24
Weak correlation
Nasdaq 100 (QQQ)
+0.22
Weak correlation
Bitcoin (BTC)
+0.05
Weak correlation
Gold (XAU)
+0.02
Weak correlation
Check Custom Correlation
Calculating correlation...
EW Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
🔴 SHORT ENTRY (click to switch)
CONSERVATIVE
$86.06
2% above current price
Lower risk, wait for rally
AGGRESSIVE
$84.37
Short at current price
Higher risk, chasing the move
Risk Management
STOP LOSS
$92.75
MAX LOSS
-7.8%
Volatility-Adjusted Stop Loss
Calculated based on RSI (24.8) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$81.75
-5% (Conservative)
-3.1% (Aggressive)
TARGET 2
$77.45
-10% (Conservative)
-8.2% (Aggressive)
TARGET 3
$73.15
-15% (Conservative)
-13.3% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for EW is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 12, 2026.Growth of $10,000
A $10,000 investment in EW in September 2016 would be worth about $21,779 today, compared with about $35,328 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in EW today could grow to about $20,915 by 2036 in the base case, with a bull case near $79,882 and a bear case around $5,476. Projections are statistical simulations, not guarantees.
EW Stock Price Prediction: 2030
CleaRank's simulation projects a price near $113 for EW by 2030 in the base case, from $84.37 today (1.3x over 4 years). The downside path ends near $48.56. These are outcomes of a Monte Carlo simulation run on EW's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $59.45 | $90.83 | $139 |
| 2028 | $53.70 | $97.79 | $178 |
| 2029 | $50.53 | $105 | $219 |
| 2030 | $48.56 | $113 | $265 |
| 2031 | $47.30 | $122 | $315 |
| 2032 | $46.52 | $131 | $371 |
| 2033 | $46.09 | $141 | $434 |
| 2034 | $45.92 | $152 | $505 |
| 2035 | $45.97 | $164 | $584 |
| 2036 | $46.20 | $176 | $674 |
Method: 10,000 simulated price paths using EW's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
EW Insider Trading Analysis
Bought
None
No open-market buys
Sold
$34.6M
54 Transactions
Insiders
18
Active Traders
Avg Transaction
$641.1K
Moderate size
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 10, 2023 | ULLEM SCOTT B
Chief Financial Officer
|
Sell | 80.7K | $7.1M |
| May 9, 2023 | SZYMAN CATHERINE M
Officer
|
Sell | 75.6K | $6.7M |
| Jan 15, 2021 | MUSSALLEM MICHAEL A
Chief Executive Officer
|
Sell | 68.6K | $6.0M |
| Nov 17, 2020 | MUSSALLEM MICHAEL A
Chief Executive Officer
|
Sell | 68.6K | $5.8M |
| Dec 14, 2020 | MUSSALLEM MICHAEL A
Chief Executive Officer
|
Sell | 68.6K | $5.8M |
| Apr 8, 2021 | MUSSALLEM MICHAEL A
Chief Executive Officer
|
Sell | 68.6K | $5.8M |
| Feb 23, 2021 | MUSSALLEM MICHAEL A
Chief Executive Officer
|
Sell | 68.6K | $5.8M |
| Oct 9, 2020 | MUSSALLEM MICHAEL A
Chief Executive Officer
|
Sell | 68.6K | $5.7M |
| Mar 9, 2021 | MUSSALLEM MICHAEL A
Chief Executive Officer
|
Sell | 68.6K | $5.7M |
| Sep 29, 2020 | MUSSALLEM MICHAEL A
Chief Executive Officer
|
Sell | 68.6K | $5.4M |
Page 1 of 1
Frequently Asked Questions
Is Edwards Lifesciences Corporation stock a buy right now?
Edwards Lifesciences Corporation (EW) is currently trading at $84.37. While Wall Street analysts have a 'Buy' consensus and a median price target of $101.50, the stock is below its key moving averages and shows moderate insider selling. The high P/E ratio of 51.60 also suggests a premium valuation.
What is the technical outlook for EW stock?
The technical outlook for EW stock is currently bearish, as it is trading below its 50-day and 200-day moving averages ($89.23 and $84.97). The RSI is in oversold territory at 24.81, which could signal a potential short-term bounce, but the overall trend indicates weakness.
What are the key risks facing Edwards Lifesciences Corporation?
Key risks include its high valuation relative to sector peers, current bearish technical indicators, and moderate insider selling. The company's earnings performance has also been inconsistent over the past year.
What is the revenue growth forecast for Edwards Lifesciences Corporation?
Revenue growth is projected to be strong, with an estimated 11.00% year-over-year increase for the current year, reaching approximately $6.8 billion, and a further 10.00% growth projected for next year, totaling around $7.4 billion.
How does EW's valuation compare to its sector averages?
Edwards Lifesciences Corporation's P/E ratio of 51.60 is significantly higher than the healthcare sector median of 31.9. Its ROE of 6.9% is also at the sector median, suggesting its valuation is not supported by superior operational efficiency compared to peers.
What is the consensus among Wall Street analysts for EW stock?
The consensus among 29 Wall Street analysts is 'Buy', with a score of 72 out of 100. The median price target is $101.50, implying an upside of 20.3% from the current price of $84.37.
What does the insider transaction data indicate for EW stock?
Insider transactions show a 'Net Seller' position, with $34.6 million in total sales and no reported purchases. This 'Moderate Sell Signal' suggests that insiders are reducing their holdings, which can be a cautionary indicator.